The ALS Ltd (ASX: ALQ) share price is on the move on Wednesday morning.
At the time of writing, the testing services company’s shares are up 3% to $12.94.
Why is the ALS share price rising?
Investors have been bidding the ALS share price higher today after the release of its annual general meeting presentation and the announcement of an acquisition.
In respect to the former, the presentation took investors through the company’s performance in FY 2021 and provided an update on trading so far in FY 2022.
ALS has started FY 2022 strongly and is expecting this to lead to solid first half profit growth. Management has provided guidance of first half underlying net profit after tax of between $115 million and $125 million. The midpoint of this guidance range represents a sizeable 49% increase on the prior corresponding period.
It advised that this reflects the strong start that it is seeing across its Life Sciences and Commodities divisions as volumes continue to improve as global activity increases.
Acquisition news
Not included in its first half guidance is the proposed acquisition of an initial 49% interest in NUVISAN, a pharmaceutical testing business with operations in Germany and France.
Management believes the acquisition provides it with the platform to expand its offering from quality control testing into ‘upstream’ services in research and development.
Growth in this area of the market is driven by major pharmaceutical companies outsourcing drug development research and testing due to increasing pricing pressure, lack of internal capability, and expertise from external providers.
ALS will initially acquire 49% of the equity in NUVISAN for a consideration of ~EUR145 million. It also has an exclusive call option to acquire the remaining equity from 1 January 2024. This option expires by 30 September 2026 at the latest.
Should this option be exercised, the remaining 51% equity in NUVISAN will be acquired at 13x adjusted EBITDA based on the 12 months preceding the purchase.
ALS’ Managing Director and CEO, Raj Naran, commented “This is a significant expansion of our Life Sciences capability as we grow our presence in the strategically important Pharmaceutical market. This will allow us to move our service offering up the supply chain into drug development and research testing, which significantly expands our addressable markets. NUVISAN offers us a platform in the key markets of Germany and France which has long been an aspiration for our Life Sciences division.”
The post Why the ALS (ASX:ALQ) share price is charging higher today appeared first on The Motley Fool Australia.
Should you invest $1,000 in ALS right now?
Before you consider ALS, you’ll want to hear this.
Motley Fool Investing expert Scott Phillips just revealed what he believes are the 5 best stocks for investors to buy right now… and ALS wasn’t one of them.
The online investing service he’s run for nearly a decade, Motley Fool Share Advisor, has provided thousands of paying members with stock picks that have doubled, tripled or even more.* And right now, Scott thinks there are 5 stocks that are better buys.
*Returns as of May 24th 2021
More reading
- Here’s why the Crown Resorts (ASX:CWN) share price is in focus today
- 3 long-term trends ASX share investors can buy into
- The Westpac share price is down 20% in 5 years. But have the dividends paid off?
- BHP (ASX:BHP) share price on watch after announcing Ring of Fire acquisition
- Own Wesfarmers (ASX:WES) shares? Here’s what to look for during reporting season
Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.
from The Motley Fool Australia https://ift.tt/2UN1tQT
Leave a Reply